|
|
|
|
AIM: New study refutes FDA's contraindication for Plavix and PPIs
Heart patients who took proton-pump inhibitors (PPIs) along with clopidogrel were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone.In addition, the PPIs did not inhibit clopidogrels therapeutic...
|
|
|
AHRQ pump clots
BC-AHRQ-pump-clots To: NATIONAL EDITORS Contact: AHRQ Public Affairs, +1-301-427-1539, or +1-301-427-1998 ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a...
|
|
|
Reflux surgery tops pills in the short term
Last Updated: 2010-03-17 13:00:25 -0400 (Reuters Health) By Megan Brooks NEW YORK (Reuters Health) - People who suffer from chronic severe stomach acid reflux have two options -- long-term medication or anti-reflux surgery.A new review of the medical...
|
|
|
Biogel adds two new surgical gloves with improved grip to non-latex polyisoprene line
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood...
|
|
|
GHX launches Procurement Suite spend management solution for hospitals
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood...
|
|
|
Cancer costs more than doubled in 40-year fight
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood...
|
|
|
Atul Gawande, MD, speaks out for checklists in the OR at AORN
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood...
|
|
|
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers
Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood clotswere only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a...
|
|
|
Forensic role of bacteria?
Patients who take a proton-pump inhibitor with medicine to prevent blood clots are less likely to be hospitalized for bleeding ulcers Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrela drug that prevents blood...
|
|
|
Proton-Pump Inhibitor Plus Clopidogrel Is Less Likely To Cause Bleeding Ulcers
Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel a drug that prevents blood clots were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a...
|
|
|
Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk
Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according...
|
|
|
Proton-Pump Inhibitor Plus Clopidogrel Is Less Likely to Cause Bleeding Ulcers
Source: Agency for Healthcare Research and Quality (AHRQ) Newswise Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel a drug that prevents blood clots were only half as likely to be hospitalized for upper digestive...
|
|
|
FDA Adds Boxed Warning To Plavix For Reduced Effectiveness In Non-responders
3/13/2010 1:31 AM ET RELATED NEWS Trade BMY now with TOP MARKET NEWS (RTTNews) - The Food and Drug Administration added a boxed warning to blood thinner drug Plavix on Friday, alerting patients and health care professionals to the drug's potential for reduced...
|
|
|
Sanofi, Bristol-Myers Strengthen Warning on Plavix (Update2)
(Adds FDA officials comment in sixth paragraph.) March 12 (Bloomberg) -- Sanofi-Aventis SA and Bristol-Myers Squibb Co.upgraded a warning for the blood thinner Plavix, saying that a genetic variant in some people keeps their bodies from unleashing the full...
|
|
|
Ogilvy Public Relations Worldwide Announces Two Senior Hires to its New York Office's Healthcare Practice
NEW YORK, March 11 /PRNewswire-USNewswire/ -- Ogilvy Public Relations Worldwide (Ogilvy PR) announced today the addition of two senior staff members to its New York, N.Y.office. Mary Coyle joins as Senior Vice President of Healthcare Media Relations and...
|
|
|
AstraZeneca buys out Mercks rights to a number of drugs
AstraZeneca is paying Merck & Co $647 million in order to get back the rights to a number of products covered by the firms US joint venture.The Anglo-Swedish drugmaker is exercising an option which will see Merck relinquish the rights to Entocort ...
|
|
|
Astra unties part of US Merck deal for $647 million
LONDON: AstraZeneca said on Monday it was exercising an option with Merck & Co to take back full rights to certain drugs marketed in the United States and would pay the U.S.group $647 million in April. The payout, which had been anticipated by...
|
|
|
AstraZeneca Will Excercise First Option In Merck JV
LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN), said Monday it has notified Merck (MRK) that it will exercise the first option to buy Entocort, Atacand and Plendil, and certain products still in development, including Brilinta, AZD3355, AZD6765 and AZD2327 for ...
|
|
|
AstraZeneca Will Excercise First Option In Merck JV
LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN), said Monday it has notified Merck (MRK) that it will exercise the first option to buy Entocort, Atacand and Plendil, and certain products still in development, including Brilinta, AZD3355, AZD6765 and AZD2327 for ...
|
|
|
AstraZeneca buys Merck drugs
AstraZeneca Plc will "excercize the option to buy Merck's interest in AstraZeneca's non-proton pump inhibitor products" (Atacand, Lexxel and Plendil, which fight high blood pressure, and Entocort, for Krohn's disease) "plus certain products in clinical...
|
|
|
AstraZeneca buys Merck drugs
AstraZeneca Plc will "excercize the option to buy Merck's interest in AstraZeneca's non-proton pump inhibitor products" (Atacand, Lexxel and Plendil, which fight high blood pressure, and Entocort, for Krohn's disease) "plus certain products in clinical...
|
|
|
AZ to pay $647M for Merck rights
AstraZeneca has exercised its option to buy out Merck's interest in some of its products, planning to pay its U.S.rival $647 million for its share of blood pressure drugs Atacand, Lexxel and Plendil, and the Crohn's disease treatment Entocort. Some in...
|
|
|
AstraZeneca Uses Option To Buy Out Some Merck Product Interest
LONDON -(Dow Jones)- U.K.pharmaceutical firm AstraZeneca PLC (AZN.LN) Monday said it will exercise an option with Merck & Co. (MRK) to retake full rights to certain drugs sold in the U.S. and pay the drug maker $647 million in April. Products...
|
|
|
Astra deal with Merck on US sales
AstraZeneca PLC said Monday it is exercising an option with Merck & Co to take back full rights to some of its drugs marketed in the United States and will pay the U.S.company $647 million. The deal is part of the planned unwinding of trading...
|
|
|
AstraZeneca Uses Option To Buy Out Some Merck Product Interest
LONDON -(Dow Jones)- U.K.pharmaceutical firm AstraZeneca PLC (AZN.LN) Monday said it will exercise an option with Merck & Co. (MRK) to retake full rights to certain drugs sold in the U.S. and pay the drug maker $647 million in April. Products...
|
